« VC funding lags in diagnostics | Main | PD3 »

November 14, 2006

Adaptation

by Peter Pitts

Despite the midterms and continued brickbats from Grassley, Waxman, Hinchey, et al., the persistent and quiet revolution going on inside the FDA continues.

The most recent example of this ray of hope is the agency’s championing of adaptive clinical trials. "Traditional" clinical trials that demonstrate a 40% efficacy rate without even attempting to isolate which 40% is expensive in financial terms and only marginally helpful in helping physicians best treat their patients. It also plays into the hands of the Evangelists of Evidence-based Medicine and the Votaries of Me-Tooism. We must think about clinical trials in new ways. It's a crucial aspect of the Critical Path.

Yesterday, Deputy Commissioner Dr. Scott Gottlieb made such a point at a Manhattan Institute talk – and it sure was refreshing.

Scott’s full remarks can be found by clicking the link below:

http://www.fda.gov/oc/speeches/2006/manhattaninst1113.html

Posted by Peter Pitts at November 14, 2006 12:30 PM

Trackback Pings

TrackBack URL for this entry:
/cgi-bin/mt-tb.cgi/77

Comments

Post a comment

Name:

Email Address:

URL:
Remember Me? YesNo

Comments: (you may use HTML tags for style)

To protect against spam, off-topic and abusive comments, all comments are reviewed before being posted to the blog. Please limit your comments to two on each topic and don't use all caps. Also, please note that some comments related to specific ownership issues are forwarded to customer assistance rather than posted here.